vs

Side-by-side financial comparison of Cytosorbents Corp (CTSO) and Forian Inc. (FORA). Click either name above to swap in a different company.

Cytosorbents Corp is the larger business by last-quarter revenue ($9.2M vs $8.0M, roughly 1.2× Forian Inc.). Forian Inc. runs the higher net margin — -22.9% vs -59.5%, a 36.6% gap on every dollar of revenue. On growth, Forian Inc. posted the faster year-over-year revenue change (37.0% vs 0.9%). Over the past eight quarters, Forian Inc.'s revenue compounded faster (27.8% CAGR vs 1.3%).

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.

Forian Inc is a specialized healthcare technology and data analytics firm offering SaaS-based real-world evidence solutions, clinical decision support tools, and operational optimization services. It serves biopharmaceutical companies, healthcare providers, and life sciences stakeholders to improve patient outcomes, accelerate research, and boost care delivery efficiency.

CTSO vs FORA — Head-to-Head

Bigger by revenue
CTSO
CTSO
1.2× larger
CTSO
$9.2M
$8.0M
FORA
Growing faster (revenue YoY)
FORA
FORA
+36.1% gap
FORA
37.0%
0.9%
CTSO
Higher net margin
FORA
FORA
36.6% more per $
FORA
-22.9%
-59.5%
CTSO
Faster 2-yr revenue CAGR
FORA
FORA
Annualised
FORA
27.8%
1.3%
CTSO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTSO
CTSO
FORA
FORA
Revenue
$9.2M
$8.0M
Net Profit
$-5.5M
$-1.8M
Gross Margin
73.7%
49.2%
Operating Margin
-47.5%
-24.4%
Net Margin
-59.5%
-22.9%
Revenue YoY
0.9%
37.0%
Net Profit YoY
27.4%
-1012.2%
EPS (diluted)
$-0.09
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTSO
CTSO
FORA
FORA
Q4 25
$9.2M
$8.0M
Q3 25
$9.5M
$7.8M
Q2 25
$9.6M
$7.5M
Q1 25
$8.7M
$7.1M
Q4 24
$9.2M
$5.8M
Q3 24
$8.6M
$4.7M
Q2 24
$8.8M
$4.8M
Q1 24
$9.0M
$4.9M
Net Profit
CTSO
CTSO
FORA
FORA
Q4 25
$-5.5M
$-1.8M
Q3 25
$-3.2M
$-151.2K
Q2 25
$1.9M
$224.8K
Q1 25
$-1.5M
$-1.1M
Q4 24
$-7.6M
$199.7K
Q3 24
$-2.8M
$-204.9K
Q2 24
$-4.3M
$-2.6M
Q1 24
$-6.1M
$-1.2M
Gross Margin
CTSO
CTSO
FORA
FORA
Q4 25
73.7%
49.2%
Q3 25
70.3%
51.6%
Q2 25
70.9%
56.8%
Q1 25
71.1%
55.6%
Q4 24
68.4%
58.3%
Q3 24
61.0%
70.1%
Q2 24
73.5%
62.2%
Q1 24
76.5%
65.1%
Operating Margin
CTSO
CTSO
FORA
FORA
Q4 25
-47.5%
-24.4%
Q3 25
-30.2%
-6.1%
Q2 25
-37.6%
0.6%
Q1 25
-44.5%
-19.8%
Q4 24
-37.1%
-24.9%
Q3 24
-56.1%
-17.0%
Q2 24
-40.4%
-62.2%
Q1 24
-51.8%
-36.3%
Net Margin
CTSO
CTSO
FORA
FORA
Q4 25
-59.5%
-22.9%
Q3 25
-33.4%
-1.9%
Q2 25
20.2%
3.0%
Q1 25
-16.9%
-16.0%
Q4 24
-82.7%
3.4%
Q3 24
-32.1%
-4.4%
Q2 24
-48.6%
-53.4%
Q1 24
-67.7%
-24.9%
EPS (diluted)
CTSO
CTSO
FORA
FORA
Q4 25
$-0.09
$-0.06
Q3 25
$-0.05
$0.00
Q2 25
$0.03
$0.01
Q1 25
$-0.02
$-0.04
Q4 24
$-0.14
$0.01
Q3 24
$-0.05
$-0.01
Q2 24
$-0.08
$-0.08
Q1 24
$-0.11
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTSO
CTSO
FORA
FORA
Cash + ST InvestmentsLiquidity on hand
$6.2M
$31.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.9M
$29.8M
Total Assets
$44.2M
$44.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTSO
CTSO
FORA
FORA
Q4 25
$6.2M
$31.6M
Q3 25
$7.5M
$28.2M
Q2 25
$10.2M
$35.6M
Q1 25
$11.6M
$35.7M
Q4 24
$3.3M
$35.1M
Q3 24
$5.7M
$49.4M
Q2 24
$8.5M
$48.0M
Q1 24
$8.6M
$47.4M
Total Debt
CTSO
CTSO
FORA
FORA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$13.8M
Q2 24
$13.7M
Q1 24
$4.4M
Stockholders' Equity
CTSO
CTSO
FORA
FORA
Q4 25
$5.9M
$29.8M
Q3 25
$9.0M
$31.1M
Q2 25
$11.6M
$30.9M
Q1 25
$14.5M
$30.0M
Q4 24
$11.1M
$30.1M
Q3 24
$13.4M
$28.4M
Q2 24
$17.4M
$27.2M
Q1 24
$19.6M
$28.1M
Total Assets
CTSO
CTSO
FORA
FORA
Q4 25
$44.2M
$44.1M
Q3 25
$45.8M
$41.3M
Q2 25
$48.0M
$48.5M
Q1 25
$50.8M
$48.6M
Q4 24
$47.4M
$47.2M
Q3 24
$47.8M
$57.5M
Q2 24
$53.4M
$58.4M
Q1 24
$47.1M
$57.5M
Debt / Equity
CTSO
CTSO
FORA
FORA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.03×
Q2 24
0.78×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTSO
CTSO
FORA
FORA
Operating Cash FlowLast quarter
$-4.8M
$3.2M
Free Cash FlowOCF − Capex
$-4.9M
FCF MarginFCF / Revenue
-53.4%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTSO
CTSO
FORA
FORA
Q4 25
$-4.8M
$3.2M
Q3 25
$-2.6M
$-439.7K
Q2 25
$-1.5M
$-344.5K
Q1 25
$-3.5M
$448.2K
Q4 24
$-2.3M
$1.7M
Q3 24
$-2.5M
$764.1K
Q2 24
$-4.8M
$-23.1K
Q1 24
$-4.8M
$-2.2M
Free Cash Flow
CTSO
CTSO
FORA
FORA
Q4 25
$-4.9M
Q3 25
$-2.6M
Q2 25
$-1.5M
Q1 25
$-3.5M
Q4 24
$-2.4M
Q3 24
$-2.6M
Q2 24
$-4.8M
Q1 24
$-4.9M
FCF Margin
CTSO
CTSO
FORA
FORA
Q4 25
-53.4%
Q3 25
-27.3%
Q2 25
-16.1%
Q1 25
-39.7%
Q4 24
-26.3%
Q3 24
-30.4%
Q2 24
-54.4%
Q1 24
-54.2%
Capex Intensity
CTSO
CTSO
FORA
FORA
Q4 25
1.2%
Q3 25
0.2%
Q2 25
0.4%
Q1 25
0.0%
Q4 24
0.8%
0.0%
Q3 24
1.8%
0.0%
Q2 24
0.2%
0.0%
Q1 24
0.5%
0.0%
Cash Conversion
CTSO
CTSO
FORA
FORA
Q4 25
Q3 25
Q2 25
-0.78×
-1.53×
Q1 25
Q4 24
8.76×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTSO
CTSO

Direct$5.1M55%
Distributors And Strategic Partners$4.2M45%

FORA
FORA

Financial Services Revenues$7.3M92%
Other$669.0K8%

Related Comparisons